SUSMED began selling its Medcle insomnia app on 1 June 2026, after the Central Social Insurance Medical Council endorsed insurance listing of the app in May, according to the company's annual securities report for the year to June 2026, filed on 29 September. The launch came a month before the year closed, so the reported numbers mostly predate it.
Revenue for the year was ¥497.2mn, up 7.4%. The operating loss widened to ¥330.2mn from ¥299.5mn, and the net loss to ¥382.7mn from ¥298.4mn. Revenue in the product segment was ¥340.2mn, of which ¥340mn was milestone income: ¥240mn from Kyorin Pharmaceutical when the first subject began using their jointly developed tinnitus app in a confirmatory trial, and ¥100mn from Asuka Pharmaceutical after a specific clinical study of a premenstrual-syndrome app showed the effect the partners expected. Kyorin alone made up 48.3% of revenue.
The report gives no figures for app sales, prescriptions or the number of medical institutions using Medcle, though management names adopting institutions and monthly prescriptions as its key indicators for the product.
On 26 August SUSMED agreed with Shionogi to set the milestone owed on insurance listing at ¥200mn and to end their sales alliance, so SUSMED will sell the app on its own. The company received the ¥200mn in September and expects to book it in the first quarter of the year ending June 2027. It describes the effect of ending the contract on that year's results as minor.
Cash and equivalents fell to ¥3.70bn from ¥4.40bn, after operating cash outflow of ¥474.5mn. SUSMED also booked a ¥67.5mn impairment on company-wide assets and says it will fund research and development from its own funds. The company's own risk section warns that uptake speed and sales could fall short of plan if competing products emerge or reimbursement points are revised.